← Leaderboards
Xin Jiang
Protego Biopharma, Inc.
$3,093,762
Attributed
$3,093,762
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2018–23$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,093,762 · 2
By mechanism
U44$2,768,762 · 1
R43$325,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Dissociation”
- Vera Hoffman · Reveal Pharma$8,343,421
- Maryam Shanechi · University Of Southern California$5,972,090
- Valery G. Voinov · E-Msion, Inc.$5,623,817
- Frank Sciavolino · Thetis Pharmaceuticals, Llc$4,824,527
- Hemali Phatnani · New York University School Of Medicine$4,449,809
- Nadya M Dimitrova · Yale University$4,407,753
Research focus
DissociationGenotypeCommercializationDisease ProgressionEarly Detection BiomarkersFamilial Amyloid NeuropathiesAffectClinical TrialsCongo RedDiagnosticClinical DevelopmentDrug DevelopmentEarly DiagnosisEarly TreatmentBiologicalBiological MarkersBiopsyAmyloidosisBody SystemAntibodiesDepositionDiagnosisAmyloid FormationImmunoassay
Grant awards (4)
Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR)$700,619
U44 · FY2023 · NS · contact PI
Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR)$1,368,143
U44 · FY2021 · NS · contact PI
Analytical Validation of Non-native Transthyretin (NNTTR) As A Candidate Biomarker for Transthyretin Amyloidoses (ATTR)$700,000
U44 · FY2020 · NS · contact PI
Development of an early diagnostic and biomarker of treatment response for TTR amyloidoses (ATTR)$325,000
R43 · FY2018 · TR · contact PI